Pharmacokinetics of Citalopram in Relation to Genetic Polymorphism of CYP2C19
Kim Brøsen
Drug Metabolism and Disposition, 2003
View PDFchevron_right
Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers
Staffan Rosenborg
British Journal of Clinical Pharmacology, 2008
View PDFchevron_right
Enantioselective analysis of citalopram and demethylcitalopram in human and rat plasma by chiral LCMS/MS: Application to pharmacokinetics
Maria Paula Marques
Chirality, 2007
View PDFchevron_right
Determination of the enantiomers of citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC
Bertrand Rochat
Chirality, 1995
View PDFchevron_right
Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway
Neil Parrott
European journal of clinical pharmacology, 2015
View PDFchevron_right
Heterozygous Mutation in CYP2C19 Significantly Increases the Concentration/Dose Ratio of Racemic Citalopram and Escitalopram (S-citalopram)
Ida Rudberg
Therapeutic Drug Monitoring, 2006
View PDFchevron_right
Identification of a Novel CYP2C19-Mediated Metabolic Pathway of S-Citalopram in Vitro
Ida Rudberg
Drug Metabolism and Disposition, 2009
View PDFchevron_right
CYP2C19- and CYP3A4-Dependent Omeprazole Metabolism in West Mexicans
Héctor González
The Journal of Clinical Pharmacology, 2003
View PDFchevron_right
In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats
Johan Ahlner
British Journal of Pharmacology, 2001
View PDFchevron_right
Variation in omeprazole pharmacokinetics in a random Iranian population: a pilot study
Farzad Kobarfard
Biopharmaceutics & Drug Disposition, 2012
View PDFchevron_right
Population pharmacokinetics of omeprazole in a random Iranian population
Caspian Journal of Internal Medicine (CJIM)
Caspian Journal of Internal Medicine, 2013
View PDFchevron_right
Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram
Antonio Carcas, Jesus Frías
European Journal of Pharmacology, 2010
View PDFchevron_right
Stereoselective Metabolism of Omeprazole by Human Cytochrome P450 Enzymes
Lars Weidolf
Drug Metabolism and Disposition the Biological Fate of Chemicals, 2000
View PDFchevron_right
Influence of quinidine, cimetidine, and ketoconazole on the enantioselective pharmacokinetics and metabolism of metoprolol in rats
Vanessa Boralli
Chirality, 2009
View PDFchevron_right
BIOEQUIVALENCE OF TWO BRANDS OF CITALOPRAM 40 mg TABLETS AFTER SINGLE ORAL ADMINISTRATION TO HEALTHY VOLUNTEERS
Simone Abdi
View PDFchevron_right
Bioequivalence and Pharmacokinetic Study of Two Different Omeprazole Capsule Formulations in Healthy Bangladeshi Volunteers
Ashraful islam
Arzneimittelforschung, 2011
View PDFchevron_right
Comparative pharmacokinetics of Omeprazole and its metabolites in poor and extensive metabolizer Pakistani healthy volunteers and a review of different studies
Dr Abad Khan
Pakistan journal of pharmaceutical sciences, 2018
View PDFchevron_right
Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram
Kim Brøsen
European Neuropsychopharmacology, 2001
View PDFchevron_right
The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to CYP2C19 and CYP3A5 genotypes
Ho-Sook Kim
British journal of clinical pharmacology, 2015
View PDFchevron_right
Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6[CYP2D6] and CYP2C19
Henrik Druid
Journal of Analytical Toxicology, 2004
View PDFchevron_right
The Pharmacology of Citalopram Enantiomers: The Antagonism by R-Citalopram on the Effect of S-Citalopram*
Connie Sanchez
Basic <html_ent glyph="@amp;" ascii="&"/> Clinical Pharmacology <html_ent glyph="@amp;" ascii="&"/> Toxicology, 2006
View PDFchevron_right
Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole
Tommy Andersson
Alimentary Pharmacology and Therapeutics, 2001
View PDFchevron_right
Bioavailability of two single-dose oral formulations of omeprazole 20 mg: an open-label, randomized sequence, two-period crossover comparison in healthy Mexican adult volunteers
Jorge Luis Poo
Clinical therapeutics, 2008
View PDFchevron_right
Enantioselective Analysis of Citalopram and its Metabolites in Postmortem Blood and Genotyping For CYD2D6 and CYP2C19
Henrik Druid
Journal of Analytical Toxicology, 2004
View PDFchevron_right
A VALIDATED RP HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF OMEPRAZOLE AND CINITAPRIDE IN COMBINED DOSAGE FORMS
Vasanth Kumar PM
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, 2012
View PDFchevron_right
Comparative pharmacokinetic analysis with two omeprazole formulations “Proceptin®” and “Losec®” in healthy subjects
Sitesh Bachar
Archives of Medical and Biomedical Research, 2015
View PDFchevron_right
Effect of clopidogrel on the hydroxylation and sulfoxidation of omeprazole: A single dose study in healthy human volunteers
Dr Abad Khan
EXCLI journal, 2017
View PDFchevron_right
The Effects on Metabolic Clearance when Administering a Potent CYP3A Autoinducer with the Prototypic CYP3A Inhibitor, Ketoconazole
Stephen Lowe
Drug Metabolism and Disposition, 2012
View PDFchevron_right